AdvanCell präsentiert auf dem ASCO GU Symposium 2026 das neuartige Phase-2-Studiendesign von ADVC001 zur Behandlung von metastasiertem Prostatakrebs
AdvanCell presented the Phase 2 study design for ADVC001, a targeted alpha radiotherapy for metastatic prostate cancer, at the ASCO GU Symposium 2026, outlining planned endpoints and patient-selection strategies.
Why it mattersPhase 2 ADVC001 data at ASCO GU requires portfolio reprioritization around targeted-alpha oncology assets.
Entities Mentioned
AdvanCellASCO GU Symposium